TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
JBM (Healthcare) Ltd. ( (HK:2161) ) has issued an announcement.
JBM (Healthcare) Limited has appointed Dr. Xu Hong Xi as a non-executive director effective from October 2, 2025. Dr. Xu brings extensive expertise in traditional Chinese medicine and pharmaceuticals, holding significant positions in academia and industry. His appointment is expected to enhance the company’s strategic direction in traditional Chinese medicine, potentially impacting its market positioning and stakeholder interests positively.
The most recent analyst rating on (HK:2161) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on JBM (Healthcare) Ltd. stock, see the HK:2161 Stock Forecast page.
More about JBM (Healthcare) Ltd.
JBM (Healthcare) Limited operates in the healthcare industry, focusing on traditional Chinese medicine and pharmaceutical products. The company is involved in research, development, and distribution of healthcare products, with a market focus on integrating traditional Chinese medicine with modern healthcare solutions.
Average Trading Volume: 1,081,044
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.41B
For a thorough assessment of 2161 stock, go to TipRanks’ Stock Analysis page.